430 related articles for article (PubMed ID: 31330086)
21. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
[TBL] [Abstract][Full Text] [Related]
22. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ
Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal.
Yu S; Zhang C; Xie KP
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188461. PubMed ID: 33157162
[TBL] [Abstract][Full Text] [Related]
24. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB
Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659
[TBL] [Abstract][Full Text] [Related]
25. ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma.
Xu L; Tong X; Zhang S; Yin F; Li X; Wei H; Li C; Guo Y; Zhao J
Tumour Biol; 2016 Oct; 37(10):13669-13677. PubMed ID: 27473084
[TBL] [Abstract][Full Text] [Related]
26. c-Src, Insulin-Like Growth Factor I Receptor, G-Protein-Coupled Receptor Kinases and Focal Adhesion Kinase are Enriched Into Prostate Cancer Cell Exosomes.
DeRita RM; Zerlanko B; Singh A; Lu H; Iozzo RV; Benovic JL; Languino LR
J Cell Biochem; 2017 Jan; 118(1):66-73. PubMed ID: 27232975
[TBL] [Abstract][Full Text] [Related]
27. Novel therapeutic targets for pancreatic cancer.
Tang SC; Chen YC
World J Gastroenterol; 2014 Aug; 20(31):10825-44. PubMed ID: 25152585
[TBL] [Abstract][Full Text] [Related]
28. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Nagaraj NS; Washington MK; Merchant NB
Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
[TBL] [Abstract][Full Text] [Related]
29. Anti-GPR56 monoclonal antibody potentiates GPR56-mediated Src-Fak signaling to modulate cell adhesion.
Chatterjee T; Zhang S; Posey TA; Jacob J; Wu L; Yu W; Francisco LE; Liu QJ; Carmon KS
J Biol Chem; 2021; 296():100261. PubMed ID: 33837725
[TBL] [Abstract][Full Text] [Related]
30. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
Hiscox S; Morgan L; Green TP; Barrow D; Gee J; Nicholson RI
Breast Cancer Res Treat; 2006 Jun; 97(3):263-74. PubMed ID: 16333527
[TBL] [Abstract][Full Text] [Related]
31. Multi-targeted molecular therapeutic approach in aggressive neuroblastoma: the effect of Focal Adhesion Kinase-Src-Paxillin system.
Kratimenos P; Koutroulis I; Marconi D; Syriopoulou V; Delivoria-Papadopoulos M; Chrousos GP; Theocharis S
Expert Opin Ther Targets; 2014 Dec; 18(12):1395-406. PubMed ID: 25189706
[TBL] [Abstract][Full Text] [Related]
32. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation.
Kiefel H; Bondong S; Pfeifer M; Schirmer U; Erbe-Hoffmann N; Schäfer H; Sebens S; Altevogt P
Carcinogenesis; 2012 Oct; 33(10):1919-29. PubMed ID: 22764136
[TBL] [Abstract][Full Text] [Related]
33. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer.
Coppola S; Carnevale I; Danen EHJ; Peters GJ; Schmidt T; Assaraf YG; Giovannetti E
Drug Resist Updat; 2017 Mar; 31():43-51. PubMed ID: 28867243
[TBL] [Abstract][Full Text] [Related]
34. Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.
Li X; Ma Q; Xu Q; Duan W; Lei J; Wu E
Curr Pharm Des; 2012; 18(17):2404-15. PubMed ID: 22372501
[TBL] [Abstract][Full Text] [Related]
35. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
[TBL] [Abstract][Full Text] [Related]
36. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
37. Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells.
Ahn K; O YM; Ji YG; Cho HJ; Lee DH
Yonsei Med J; 2018 Aug; 59(6):727-735. PubMed ID: 29978609
[TBL] [Abstract][Full Text] [Related]
38. Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia.
Creeden JF; Alganem K; Imami AS; Henkel ND; Brunicardi FC; Liu SH; Shukla R; Tomar T; Naji F; McCullumsmith RE
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233470
[TBL] [Abstract][Full Text] [Related]
39. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
40. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
